Sutro Biopharma Cash Flow Conversion Efficiency
Sutro Biopharma cash flow conversion efficiency. Based on the latest financial reports, Sutro Biopharma (STRO) has a cash flow conversion efficiency ratio of 0.371x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.29 Million) by net assets ($-103.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sutro Biopharma (2016–2025)
Cash flow conversion efficiency of Sutro Biopharma from 2016 to 2025. This chart illustrates how Sutro Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Sutro Biopharma (STRO) stock price for real-time trading data and today's change.
Sutro Biopharma Cash Flow Conversion Ratio Explained
Sutro Biopharma cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sutro Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sutro Biopharma ranked by their cash flow conversion efficiency. Also see how much is Sutro Biopharma worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Intops Co. Ltd
KQ:049070
|
0.011x |
|
Tantalus Systems Holding Inc
TO:GRID
|
-0.309x |
|
Thai Rayon Public Company Limited
BK:TR
|
-0.018x |
|
PHX Minerals Inc
NYSE:PHX
|
0.034x |
|
Wallbridge Mining Company Limited
TO:WM
|
-0.003x |
|
Daehan Steel
KO:084010
|
0.024x |
|
AB Klaipedos nafta
F:XIC
|
-0.143x |
|
WEST RED LAKE GOLD MINES
F:UJ0
|
0.167x |
Annual Cash Flow Conversion Efficiency for Sutro Biopharma (2016–2025)
The table below shows the annual cash flow conversion efficiency of Sutro Biopharma from 2016 to 2025. Review STRO cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-132.45 Million | $-177.23 Million | 1.338x | +131.16% |
| 2024-12-31 | $44.60 Million | $-191.54 Million | -4.295x | -475.79% |
| 2023-12-31 | $149.65 Million | $-111.62 Million | -0.746x | -4661.44% |
| 2022-12-31 | $217.05 Million | $3.55 Million | 0.016x | +105.06% |
| 2021-12-31 | $252.56 Million | $-81.68 Million | -0.323x | -58.38% |
| 2020-12-31 | $332.05 Million | $-67.80 Million | -0.204x | +69.29% |
| 2019-12-31 | $97.79 Million | $-65.02 Million | -0.665x | -789.62% |
| 2018-12-31 | $131.54 Million | $12.68 Million | 0.096x | -71.65% |
| 2017-12-31 | $-109.00 Million | $-37.07 Million | 0.340x | +135.06% |
| 2016-12-31 | $-90.90 Million | $-13.15 Million | 0.145x | -- |
About Sutro Biopharma
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid… Read more